Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions
|
摘要
AIM To investigate the main current etiologies of cirrhosis in Mexico.METHODS We performed a cross-sectional retrospective multicenter study that included eight hospitals in different areas of Mexico. These hospitals provide health care to people of diverse social classes. The inclusion criteria were a histological, clinical, biochemical, endoscopic, or imaging diagnosis of liver cirrhosis. Data were obtained during a 5-year period(January 2012-December 2017). RESULTS A total of 1210 patients were included. The mean age was 62.5 years(SD = 12.1), and the percentages of men and women were similar(52.0% vs 48.0%). The most frequent causes of liver cirrhosis were hepatitis C virus(HCV)(36.2%), alcoholic liver disease(ALD)(31.2%), and nonalcoholic steatohepatitis(23.2%), and the least frequent were hepatitis B virus(1.1%), autoimmune disorders(7.3%), and other conditions(1.0%).CONCLUSION HCV and ALD are the most frequent causes of cirrhosis in Mexico. However, we note that non-alcoholic fatty liver disease(NAFLD) as an etiology of cirrhosis increased by 100% compared with the rate noted previously. We conclude that NAFLD will soon become one of the most frequent etiologies of liver cirrhosis in Mexico.
AIM To investigate the main current etiologies of cirrhosis in Mexico.METHODS We performed a cross-sectional retrospective multicenter study that included eight hospitals in different areas of Mexico. These hospitals provide health care to people of diverse social classes. The inclusion criteria were a histological, clinical, biochemical, endoscopic, or imaging diagnosis of liver cirrhosis. Data were obtained during a 5-year period(January 2012-December 2017). RESULTS A total of 1210 patients were included. The mean age was 62.5 years(SD = 12.1), and the percentages of men and women were similar(52.0% vs 48.0%). The most frequent causes of liver cirrhosis were hepatitis C virus(HCV)(36.2%), alcoholic liver disease(ALD)(31.2%), and nonalcoholic steatohepatitis(23.2%), and the least frequent were hepatitis B virus(1.1%), autoimmune disorders(7.3%), and other conditions(1.0%).CONCLUSION HCV and ALD are the most frequent causes of cirrhosis in Mexico. However, we note that non-alcoholic fatty liver disease(NAFLD) as an etiology of cirrhosis increased by 100% compared with the rate noted previously. We conclude that NAFLD will soon become one of the most frequent etiologies of liver cirrhosis in Mexico.
AIM To investigate the main current etiologies of cirrhosis in Mexico.METHODS We performed a cross-sectional retrospective multicenter study that included eight hospitals in different areas of Mexico. These hospitals provide health care to people of diverse social classes. The inclusion criteria were a histological, clinical, biochemical, endoscopic, or imaging diagnosis of liver cirrhosis. Data were obtained during a 5-year period(January 2012-December 2017). RESULTS A total of 1210 patients were included. The mean age was 62.5 years(SD = 12.1), and the percentages of men and women were similar(52.0% vs 48.0%). The most frequent causes of liver cirrhosis were hepatitis C virus(HCV)(36.2%), alcoholic liver disease(ALD)(31.2%), and nonalcoholic steatohepatitis(23.2%), and the least frequent were hepatitis B virus(1.1%), autoimmune disorders(7.3%), and other conditions(1.0%).CONCLUSION HCV and ALD are the most frequent causes of cirrhosis in Mexico. However, we note that non-alcoholic fatty liver disease(NAFLD) as an etiology of cirrhosis increased by 100% compared with the rate noted previously. We conclude that NAFLD will soon become one of the most frequent etiologies of liver cirrhosis in Mexico.
引文
1 Bataller R,Brenner DA.Liver fibrosis.J Clin Invest 2005;115:209-218[PMID:15690074 DOI:10.1172/JCI24282]
2 Friedman SL.Liver fibrosis--from bench to bedside.J Hepatol2003;38 Suppl 1:S38-S53[PMID:12591185 DOI:10.1016/S0168-8278(02)00429-4]
3 Schuppan D,Afdhal NH.Liver cirrhosis.Lancet 2008;371:838-851[PMID:18328931 DOI:10.1016/S0140-6736(08)60383-9]
4 Mokdad AA,Lopez AD,Shahraz S,Lozano R,Mokdad AH,Stanaway J,Murray CJ,Naghavi M.Liver cirrhosis mortality in187 countries between 1980 and 2010:a systematic analysis.BMCMed 2014;12:145[PMID:25242656 DOI:10.1186/s12916-014-0145-y]
5 Byass P.The global burden of liver disease:a challenge for methods and for public health.BMC Med 2014;12:159[PMID:25286285 DOI:10.1186/s12916-014-0159-5]
6 Scaglione S,Kliethermes S,Cao G,Shoham D,Durazo R,Luke A,Volk ML.The Epidemiology of Cirrhosis in the United States:A Population-based Study.J Clin Gastroenterol 2015;49:690-696[PMID:25291348 DOI:10.1097/MCG.0000000000000208]
7 Setiawan VW,Stram DO,Porcel J,Lu SC,Le Marchand L,Noureddin M.Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups:The multiethnic cohort.Hepatology 2016;64:1969-1977[PMID:27301913 DOI:10.1002/hep.28677]
8 Blachier M,Leleu H,Peck-Radosavljevic M,Valla DC,Roudot-Thoraval F.The burden of liver disease in Europe:a review of av-ailable epidemiological data.J Hepatol 2013;58:593-608[PMID:23419824 DOI:10.1016/j.jhep.2012.12.005]
9 Hatami B,Ashtari S,Sharifian A,Rahmani Seraji H,Khalili E,Hatami Y,Zali MR.Changing the cause of liver cirrhosis from hepatitis B virus to fatty liver in Iranian patients.Gastroenterol Hepatol Bed Bench 2017;10:S20-S26[PMID:29511467]
10 Marcellin P,Kutala BK.Liver diseases:A major,neglected global public health problem requiring urgent actions and large-scale screening.Liver Int 2018;38 Suppl 1:2-6[PMID:29427496 DOI:10.1111/liv.13682]
11 Sayiner M,Koenig A,Henry L,Younossi ZM.Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.Clin Liver Dis 2016;20:205-214[PMID:27063264 DOI:10.1016/j.cld.2015.10.001]
12 Younossi ZM,Blissett D,Blissett R,Henry L,Stepanova M,Younossi Y,Racila A,Hunt S,Beckerman R.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Hepatology 2016;64:1577-1586[PMID:27543837 DOI:10.1002/hep.28785]
13 Calzadilla Bertot L,Adams LA.The Natural Course of Non-Alcoholic Fatty Liver Disease.Int J Mol Sci 2016;17:E774[PMID:27213358 DOI:10.3390/ijms17050774]
14 Chedid MF.Nonalcoholic Steatohepatitis:The Second Leading In-dication for Liver Transplantation in the USA.Dig Dis Sci 2017;62:2621-2622[PMID:28840385 DOI:10.1007/s10620-017-4724-6]
15 Cholankeril G,Wong RJ,Hu M,Perumpail RB,Yoo ER,Puri P,Younossi ZM,Harrison SA,Ahmed A.Liver Transplantation for Nonalcoholic Steatohepatitis in the US:Temporal Trends and Outcomes.Dig Dis Sci 2017;62:2915-2922[PMID:28744836DOI:10.1007/s10620-017-4684-x]
16 Rtveladze K,Marsh T,Barquera S,Sanchez Romero LM,Levy D,Melendez G,Webber L,Kilpi F,McPherson K,Brown M.Obesity prevalence in Mexico:impact on health and economic burden.Public Health Nutr 2014;17:233-239[PMID:23369462 DOI:10.1017/S1368980013000086]
17 López-Velázquez JA,Silva-Vidal KV,Ponciano-Rodríguez G,Chávez-Tapia NC,Arrese M,Uribe M,Méndez-Sánchez N.The prevalence of nonalcoholic fatty liver disease in the Americas.Ann Hepatol 2014;13:166-178[PMID:24552858]
18 Valdivia-Correa B,Chablé-Montero F,Uribe M,Méndez-Sánchez N.Epidemiology of chronic autoimmune liver disease:a histopathological study in third-level hospital in Mexico City.Rev Invest Med Sur Mex 2016;1:43-48
19 Saunders JB,Aasland OG,Babor TF,de la Fuente JR,Grant M.Development of the Alcohol Use Disorders Identification Test(AUDIT):WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II.Addiction 1993;88:791-804[PMID:8329970 DOI:10.1111/j.1360-0443.1993.tb02093.x]
20 Cruz-Ramón V,Chinchilla-López P,Ramírez-Pérez O,Méndez-Sánchez N.Effects of Portal Vein Thrombosis on the Outcomes of Liver Cirrhosis:A Mexican Perspective.J Transl Int Med 2017;5:189-191[PMID:29340273 DOI:10.1515/jtim-2017-0031]
21 Méndez-Sánchez N,Aguilar-Ramírez JR,Reyes A,Dehesa M,Juórez A,Cast?eda B,Sánchez-Avila F,Poo JL,Guevara González L,Lizardi J,Valdovinos MA,Uribe M,Contreras AM,Tirado P,Aguirre J,Rivera-Benítez C,Santiago-Santiago R,Bosques-Padilla F,Mu?oz L,Guerroro A,Ramos M,Rodríguez-Hernández H,Jacobo-Karam J;Grupo de Estudio,Asociación Mexicana de Hepatología.Etiology of liver cirrhosis in Mexico.Ann Hepatol2004;3:30-33[PMID:15118577]
22 Younossi ZM,Stepanova M,Afendy M,Fang Y,Younossi Y,Mir H,Srishord M.Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to2008.Clin Gastroenterol Hepatol 2011;9:524-530.e1;quiz e60[PMID:21440669 DOI:10.1016/j.cgh.2011.03.020]
23 Ratib S,Fleming KM,Crooks CJ,Walker AJ,West J.Causes of death in people with liver cirrhosis in England compared with the general population:a population-based cohort study.Am JGastroenterol 2015;110:1149-1158[PMID:26169512 DOI:10.1038/ajg.2015.191]
24 Michitaka K,Nishiguchi S,Aoyagi Y,Hiasa Y,Tokumoto Y,Onji M;Japan Etiology of Liver Cirrhosis Study Group.Etiology of liver cirrhosis in Japan:a nationwide survey.J Gastroenterol 2010;45:86-94[PMID:19789837 DOI:10.1007/s00535-009-0128-5]
25 Murray CJ,Vos T,Lozano R,Naghavi M,Flaxman AD,Michaud C,Ezzati M,Shibuya K,Salomon JA,Abdalla S,Aboyans V,Abraham J,Ackerman I,Aggarwal R,Ahn SY,Ali MK,Alvarado M,Anderson HR,Anderson LM,Andrews KG,Atkinson C,Baddour LM,Bahalim AN,Barker-Collo S,Barrero LH,Bartels DH,Basá?ez MG,Baxter A,Bell ML,Benjamin EJ,Bennett D,BernabéE,Bhalla K,Bhandari B,Bikbov B,Bin Abdulhak A,Birbeck G,Black JA,Blencowe H,Blore JD,Blyth F,Bolliger I,Bonaventure A,Boufous S,Bourne R,Boussinesq M,Braithwaite T,Brayne C,Bridgett L,Brooker S,Brooks P,Brugha TS,Bryan-Hancock C,Bucello C,Buchbinder R,Buckle G,Budke CM,Burch M,Burney P,Burstein R,Calabria B,Campbell B,Canter CE,Carabin H,Carapetis J,Carmona L,Cella C,Charlson F,Chen H,Cheng AT,Chou D,Chugh SS,Coffeng LE,Colan SD,Colquhoun S,Colson KE,Condon J,Connor MD,Cooper LT,Corriere M,Cortinovis M,de Vaccaro KC,Couser W,Cowie BC,Criqui MH,Cross M,Dabhadkar KC,Dahiya M,Dahodwala N,Damsere-Derry J,Danaei G,Davis A,De Leo D,Degenhardt L,Dellavalle R,Delossantos A,Denenberg J,Derrett S,Des Jarlais DC,Dharmaratne SD,Dherani M,Diaz-Torne C,Dolk H,Dorsey ER,Driscoll T,Duber H,Ebel B,Edmond K,Elbaz A,Ali SE,Erskine H,Erwin PJ,Espindola P,Ewoigbokhan SE,Farzadfar F,Feigin V,Felson DT,Ferrari A,Ferri CP,Fèvre EM,Finucane MM,Flaxman S,Flood L,Foreman K,Forouzanfar MH,Fowkes FG,Fransen M,Freeman MK,Gabbe BJ,Gabriel SE,Gakidou E,Ganatra HA,Garcia B,Gaspari F,Gillum RF,Gmel G,Gonzalez-Medina D,Gosselin R,Grainger R,Grant B,Groeger J,Guillemin F,Gunnell D,Gupta R,Haagsma J,Hagan H,Halasa YA,Hall W,Haring D,Haro JM,Harrison JE,Havmoeller R,Hay RJ,Higashi H,Hill C,Hoen B,Hoffman H,Hotez PJ,Hoy D,Huang JJ,Ibeanusi SE,Jacobsen KH,James SL,Jarvis D,Jasrasaria R,Jayaraman S,Johns N,Jonas JB,Karthikeyan G,Kassebaum N,Kawakami N,Keren A,Khoo JP,King CH,Knowlton LM,Kobusingye O,Koranteng A,Krishnamurthi R,Laden F,Lalloo R,Laslett LL,Lathlean T,Leasher JL,Lee YY,Leigh J,Levinson D,Lim SS,Limb E,Lin JK,Lipnick M,Lipshultz SE,Liu W,Loane M,Ohno SL,Lyons R,Mabweijano J,MacIntyre MF,Malekzadeh R,Mallinger L,Manivannan S,Marcenes W,March L,Margolis DJ,Marks GB,Marks R,Matsumori A,Matzopoulos R,Mayosi BM,McAnulty JH,McDermott MM,McGill N,McGrath J,Medina-Mora ME,Meltzer M,Mensah GA,Merriman TR,Meyer AC,Miglioli V,Miller M,Miller TR,Mitchell PB,Mock C,Mocumbi AO,Moffitt TE,Mokdad AA,Monasta L,Montico M,Moradi-Lakeh M,Moran A,Morawska L,Mori R,Murdoch ME,Mwaniki MK,Naidoo K,Nair MN,Naldi L,Narayan KM,Nelson PK,Nelson RG,Nevitt MC,Newton CR,Nolte S,Norman P,Norman R,O’Donnell M,O’Hanlon S,Olives C,Omer SB,Ortblad K,Osborne R,Ozgediz D,Page A,Pahari B,Pandian JD,Rivero AP,Patten SB,Pearce N,Padilla RP,Perez-Ruiz F,Perico N,Pesudovs K,Phillips D,Phillips MR,Pierce K,Pion S,Polanczyk GV,Polinder S,Pope CA 3rd,Popova S,Porrini E,Pourmalek F,Prince M,Pullan RL,Ramaiah KD,Ranganathan D,Razavi H,Regan M,Rehm JT,Rein DB,Remuzzi G,Richardson K,Rivara FP,Roberts T,Robinson C,De Leòn FR,Ronfani L,Room R,Rosenfeld LC,Rushton L,Sacco RL,Saha S,Sampson U,Sanchez-Riera L,Sanman E,Schwebel DC,Scott JG,Segui-Gomez M,Shahraz S,Shepard DS,Shin H,Shivakoti R,Singh D,Singh GM,Singh JA,Singleton J,Sleet DA,Sliwa K,Smith E,Smith JL,Stapelberg NJ,Steer A,Steiner T,Stolk WA,Stovner LJ,Sudfeld C,Syed S,Tamburlini G,Tavakkoli M,Taylor HR,Taylor JA,Taylor WJ,Thomas B,Thomson WM,Thurston GD,Tleyjeh IM,Tonelli M,Towbin JA,Truelsen T,Tsilimbaris MK,Ubeda C,Undurraga EA,van der Werf MJ,van Os J,Vavilala MS,Venketasubramanian N,Wang M,Wang W,Watt K,Weatherall DJ,Weinstock MA,Weintraub R,Weisskopf MG,Weissman MM,White RA,Whiteford H,Wiebe N,Wiersma ST,Wilkinson JD,Williams HC,Williams SR,Witt E,Wolfe F,Woolf AD,Wulf S,Yeh PH,Zaidi AK,Zheng ZJ,Zonies D,Lopez AD,AlMazroa MA,Memish ZA.Disability-adjusted life years(DALYs)for 291 diseases and injuries in 21 regions,1990-2010:a systematic analysis for the Global Burden of Disease Study 2010.Lancet 2012;380:2197-2223[PMID:23245608 DOI:10.1016/S0140-6736(12)61689-4]
26 Wang FS,Fan JG,Zhang Z,Gao B,Wang HY.The global burden of liver disease:the major impact of China.Hepatology 2014;60:2099-2108[PMID:25164003 DOI:10.1002/hep.27406]
27 Gon?alves PL,Zago-Gomes Mda P,Marques CC,Mendon?a AT,Gon?alves CS,Pereira FE.Etiology of liver cirrhosis in Brazil:chronic alcoholism and hepatitis viruses in liver cirrhosis diagno-sed in the state of Espírito Santo.Clinics(Sao Paulo)2013;68:291-295[PMID:23644846 DOI:10.6061/clinics/2013(03)OA02]
28 Mukherjee PS,Vishnubhatla S,Amarapurkar DN,Das K,Sood A,Chawla YK,Eapen CE,Boddu P,Thomas V,Varshney S,Hidangmayum DS,Bhaumik P,Thakur B,Acharya SK,Chowdhury A.Etiology and mode of presentation of chronic liver diseases in India:A multi centric study.PLo S One 2017;12:e0187033[PMID:29073197 DOI:10.1371/journal.pone.0187033]
29 Méndez-Sánchez N,Villa AR,Chávez-Tapia NC,Ponciano-Rodriguez G,Almeda-Valdés P,González D,Uribe M.Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data.Ann Hepatol 2005;4:52-55[PMID:15798662]
30 Torres-Valadez R,Roman S,Jose-Abrego A,Sepulveda-Villegas M,Ojeda-Granados C,Rivera-I?iguez I,Panduro A.Early Detection of Liver Damage in Mexican Patients with Chronic Liver Disease.J Transl Int Med 2017;5:49-57[PMID:28680839DOI:10.1515/jtim-2017-0003]
31 Arrese M,Feldstein AE.Nash-Related Cirrhosis:An Occult Liver Disease Burden.Hepatol Commun 2017;1:84-86[PMID:29335681 DOI:10.1002/hep4.1033]
32 Younossi ZM,Koenig AB,Abdelatif D,Fazel Y,Henry L,Wymer M.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes.Hepatology 2016;64:73-84[PMID:26707365 DOI:10.1002/hep.28431]
33 Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLDin Asia.J Hepatol 2017;67:862-873[PMID:28642059 DOI:10.1016/j.jhep.2017.06.003]
34 Wong VW.Nonalcoholic fatty liver disease in Asia:a story of growth.J Gastroenterol Hepatol 2013;28:18-23[PMID:23094755DOI:10.1111/jgh.12011]
35 Kojima S,Watanabe N,Numata M,Ogawa T,Matsuzaki S.Increase in the prevalence of fatty liver in Japan over the past 12years:analysis of clinical background.J Gastroenterol 2003;38:954-961[PMID:14614602 DOI:10.1007/s00535-003-1178-8]
36 Hu X,Huang Y,Bao Z,Wang Y,Shi D,Liu F,Gao Z,Yu X.Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units.BMC Gastroenterol 2012;12:123[PMID:22978800 DOI:10.1186/1471-230X-12-123]
37 Wei JL,Leung JC,Loong TC,Wong GL,Yeung DK,Chan RS,Chan HL,Chim AM,Woo J,Chu WC,Wong VW.Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients:A Population Study Using Proton-Magnetic Resonance Spectroscopy.Am J Gastroenterol 2015;110:1306-14;quiz 1315[PMID:26215532 DOI:10.1038/ajg.2015.235]
38 Li H,Wang YJ,Tan K,Zeng L,Liu L,Liu FJ,Zhou TY,Chen EQ,Tang H.Prevalence and risk factors of fatty liver disease in Chengdu,Southwest China.Hepatobiliary Pancreat Dis Int 2009;8:377-382[PMID:19666406]
39 Nader LA,de Mattos AA,Bastos GA.Burden of liver disease in Brazil.Liver Int 2014;34:844-849[PMID:24422599 DOI:10.1111/liv.12470]
40 de Carvalho JR,Villela-Nogueira CA,Perez RM,Portugal FB,Flor LS,Campos MR,Schramm JMA.Burden of Chronic Viral Hepatitis and Liver Cirrhosis in Brazil-the Brazilian Global Burden of Disease Study.Ann Hepatol 2017;16:893-900[PMID:29055917 DOI:10.5604/01.3001.0010.5280]
41 Pereira LM,Martelli CM,Moreira RC,Merchan-Hamman E,Stein AT,Cardoso MR,Figueiredo GM,Montarroyos UR,Braga C,Turchi MD,Coral G,Crespo D,Lima ML,Alencar LC,Costa M,dos Santos AA,Ximenes RA.Prevalence and risk factors of Hepatitis C virus infection in Brazil,2005 through 2009:a cross-sectional study.BMC Infect Dis 2013;13:60[PMID:23374914DOI:10.1186/1471-2334-13-60]
42 Singal AK,Anand BS.Recent trends in the epidemiology of alcoholic liver disease.Clin Liver Dis 2013;2:53-56[DOI:10.1002/cld.168]
43 Ratib S,West J,Fleming KM.Liver cirrhosis in England-an observational study:are we measuring its burden occurrence correctly?BMJ Open 2017;7:e013752[PMID:28710203 DOI:10.1136/bmjopen-2016-013752]
44 Fleming KM,Aithal GP,Solaymani-Dodaran M,Card TR,West J.Incidence and prevalence of cirrhosis in the United Kingdom,1992-2001:a general population-based study.J Hepatol 2008;49:732-738[PMID:18667256 DOI:10.1016/j.jhep.2008.05.023]
45 Armstrong MJ,Houlihan DD,Bentham L,Shaw JC,Cramb R,Olliff S,Gill PS,Neuberger JM,Lilford RJ,Newsome PN.Pre-sence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.J Hepatol 2012;56:234-240[PMID:21703178 DOI:10.1016/j.jhep.2011.03.020]
46 Davis GL,Albright JE,Cook SF,Rosenberg DM.Projecting future complications of chronic hepatitis C in the United States.Liver Transpl 2003;9:331-338[PMID:12682882 DOI:10.1053/jlts.2003.50073]
2 Friedman SL.Liver fibrosis--from bench to bedside.J Hepatol2003;38 Suppl 1:S38-S53[PMID:12591185 DOI:10.1016/S0168-8278(02)00429-4]
3 Schuppan D,Afdhal NH.Liver cirrhosis.Lancet 2008;371:838-851[PMID:18328931 DOI:10.1016/S0140-6736(08)60383-9]
4 Mokdad AA,Lopez AD,Shahraz S,Lozano R,Mokdad AH,Stanaway J,Murray CJ,Naghavi M.Liver cirrhosis mortality in187 countries between 1980 and 2010:a systematic analysis.BMCMed 2014;12:145[PMID:25242656 DOI:10.1186/s12916-014-0145-y]
5 Byass P.The global burden of liver disease:a challenge for methods and for public health.BMC Med 2014;12:159[PMID:25286285 DOI:10.1186/s12916-014-0159-5]
6 Scaglione S,Kliethermes S,Cao G,Shoham D,Durazo R,Luke A,Volk ML.The Epidemiology of Cirrhosis in the United States:A Population-based Study.J Clin Gastroenterol 2015;49:690-696[PMID:25291348 DOI:10.1097/MCG.0000000000000208]
7 Setiawan VW,Stram DO,Porcel J,Lu SC,Le Marchand L,Noureddin M.Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups:The multiethnic cohort.Hepatology 2016;64:1969-1977[PMID:27301913 DOI:10.1002/hep.28677]
8 Blachier M,Leleu H,Peck-Radosavljevic M,Valla DC,Roudot-Thoraval F.The burden of liver disease in Europe:a review of av-ailable epidemiological data.J Hepatol 2013;58:593-608[PMID:23419824 DOI:10.1016/j.jhep.2012.12.005]
9 Hatami B,Ashtari S,Sharifian A,Rahmani Seraji H,Khalili E,Hatami Y,Zali MR.Changing the cause of liver cirrhosis from hepatitis B virus to fatty liver in Iranian patients.Gastroenterol Hepatol Bed Bench 2017;10:S20-S26[PMID:29511467]
10 Marcellin P,Kutala BK.Liver diseases:A major,neglected global public health problem requiring urgent actions and large-scale screening.Liver Int 2018;38 Suppl 1:2-6[PMID:29427496 DOI:10.1111/liv.13682]
11 Sayiner M,Koenig A,Henry L,Younossi ZM.Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.Clin Liver Dis 2016;20:205-214[PMID:27063264 DOI:10.1016/j.cld.2015.10.001]
12 Younossi ZM,Blissett D,Blissett R,Henry L,Stepanova M,Younossi Y,Racila A,Hunt S,Beckerman R.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Hepatology 2016;64:1577-1586[PMID:27543837 DOI:10.1002/hep.28785]
13 Calzadilla Bertot L,Adams LA.The Natural Course of Non-Alcoholic Fatty Liver Disease.Int J Mol Sci 2016;17:E774[PMID:27213358 DOI:10.3390/ijms17050774]
14 Chedid MF.Nonalcoholic Steatohepatitis:The Second Leading In-dication for Liver Transplantation in the USA.Dig Dis Sci 2017;62:2621-2622[PMID:28840385 DOI:10.1007/s10620-017-4724-6]
15 Cholankeril G,Wong RJ,Hu M,Perumpail RB,Yoo ER,Puri P,Younossi ZM,Harrison SA,Ahmed A.Liver Transplantation for Nonalcoholic Steatohepatitis in the US:Temporal Trends and Outcomes.Dig Dis Sci 2017;62:2915-2922[PMID:28744836DOI:10.1007/s10620-017-4684-x]
16 Rtveladze K,Marsh T,Barquera S,Sanchez Romero LM,Levy D,Melendez G,Webber L,Kilpi F,McPherson K,Brown M.Obesity prevalence in Mexico:impact on health and economic burden.Public Health Nutr 2014;17:233-239[PMID:23369462 DOI:10.1017/S1368980013000086]
17 López-Velázquez JA,Silva-Vidal KV,Ponciano-Rodríguez G,Chávez-Tapia NC,Arrese M,Uribe M,Méndez-Sánchez N.The prevalence of nonalcoholic fatty liver disease in the Americas.Ann Hepatol 2014;13:166-178[PMID:24552858]
18 Valdivia-Correa B,Chablé-Montero F,Uribe M,Méndez-Sánchez N.Epidemiology of chronic autoimmune liver disease:a histopathological study in third-level hospital in Mexico City.Rev Invest Med Sur Mex 2016;1:43-48
19 Saunders JB,Aasland OG,Babor TF,de la Fuente JR,Grant M.Development of the Alcohol Use Disorders Identification Test(AUDIT):WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II.Addiction 1993;88:791-804[PMID:8329970 DOI:10.1111/j.1360-0443.1993.tb02093.x]
20 Cruz-Ramón V,Chinchilla-López P,Ramírez-Pérez O,Méndez-Sánchez N.Effects of Portal Vein Thrombosis on the Outcomes of Liver Cirrhosis:A Mexican Perspective.J Transl Int Med 2017;5:189-191[PMID:29340273 DOI:10.1515/jtim-2017-0031]
21 Méndez-Sánchez N,Aguilar-Ramírez JR,Reyes A,Dehesa M,Juórez A,Cast?eda B,Sánchez-Avila F,Poo JL,Guevara González L,Lizardi J,Valdovinos MA,Uribe M,Contreras AM,Tirado P,Aguirre J,Rivera-Benítez C,Santiago-Santiago R,Bosques-Padilla F,Mu?oz L,Guerroro A,Ramos M,Rodríguez-Hernández H,Jacobo-Karam J;Grupo de Estudio,Asociación Mexicana de Hepatología.Etiology of liver cirrhosis in Mexico.Ann Hepatol2004;3:30-33[PMID:15118577]
22 Younossi ZM,Stepanova M,Afendy M,Fang Y,Younossi Y,Mir H,Srishord M.Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to2008.Clin Gastroenterol Hepatol 2011;9:524-530.e1;quiz e60[PMID:21440669 DOI:10.1016/j.cgh.2011.03.020]
23 Ratib S,Fleming KM,Crooks CJ,Walker AJ,West J.Causes of death in people with liver cirrhosis in England compared with the general population:a population-based cohort study.Am JGastroenterol 2015;110:1149-1158[PMID:26169512 DOI:10.1038/ajg.2015.191]
24 Michitaka K,Nishiguchi S,Aoyagi Y,Hiasa Y,Tokumoto Y,Onji M;Japan Etiology of Liver Cirrhosis Study Group.Etiology of liver cirrhosis in Japan:a nationwide survey.J Gastroenterol 2010;45:86-94[PMID:19789837 DOI:10.1007/s00535-009-0128-5]
25 Murray CJ,Vos T,Lozano R,Naghavi M,Flaxman AD,Michaud C,Ezzati M,Shibuya K,Salomon JA,Abdalla S,Aboyans V,Abraham J,Ackerman I,Aggarwal R,Ahn SY,Ali MK,Alvarado M,Anderson HR,Anderson LM,Andrews KG,Atkinson C,Baddour LM,Bahalim AN,Barker-Collo S,Barrero LH,Bartels DH,Basá?ez MG,Baxter A,Bell ML,Benjamin EJ,Bennett D,BernabéE,Bhalla K,Bhandari B,Bikbov B,Bin Abdulhak A,Birbeck G,Black JA,Blencowe H,Blore JD,Blyth F,Bolliger I,Bonaventure A,Boufous S,Bourne R,Boussinesq M,Braithwaite T,Brayne C,Bridgett L,Brooker S,Brooks P,Brugha TS,Bryan-Hancock C,Bucello C,Buchbinder R,Buckle G,Budke CM,Burch M,Burney P,Burstein R,Calabria B,Campbell B,Canter CE,Carabin H,Carapetis J,Carmona L,Cella C,Charlson F,Chen H,Cheng AT,Chou D,Chugh SS,Coffeng LE,Colan SD,Colquhoun S,Colson KE,Condon J,Connor MD,Cooper LT,Corriere M,Cortinovis M,de Vaccaro KC,Couser W,Cowie BC,Criqui MH,Cross M,Dabhadkar KC,Dahiya M,Dahodwala N,Damsere-Derry J,Danaei G,Davis A,De Leo D,Degenhardt L,Dellavalle R,Delossantos A,Denenberg J,Derrett S,Des Jarlais DC,Dharmaratne SD,Dherani M,Diaz-Torne C,Dolk H,Dorsey ER,Driscoll T,Duber H,Ebel B,Edmond K,Elbaz A,Ali SE,Erskine H,Erwin PJ,Espindola P,Ewoigbokhan SE,Farzadfar F,Feigin V,Felson DT,Ferrari A,Ferri CP,Fèvre EM,Finucane MM,Flaxman S,Flood L,Foreman K,Forouzanfar MH,Fowkes FG,Fransen M,Freeman MK,Gabbe BJ,Gabriel SE,Gakidou E,Ganatra HA,Garcia B,Gaspari F,Gillum RF,Gmel G,Gonzalez-Medina D,Gosselin R,Grainger R,Grant B,Groeger J,Guillemin F,Gunnell D,Gupta R,Haagsma J,Hagan H,Halasa YA,Hall W,Haring D,Haro JM,Harrison JE,Havmoeller R,Hay RJ,Higashi H,Hill C,Hoen B,Hoffman H,Hotez PJ,Hoy D,Huang JJ,Ibeanusi SE,Jacobsen KH,James SL,Jarvis D,Jasrasaria R,Jayaraman S,Johns N,Jonas JB,Karthikeyan G,Kassebaum N,Kawakami N,Keren A,Khoo JP,King CH,Knowlton LM,Kobusingye O,Koranteng A,Krishnamurthi R,Laden F,Lalloo R,Laslett LL,Lathlean T,Leasher JL,Lee YY,Leigh J,Levinson D,Lim SS,Limb E,Lin JK,Lipnick M,Lipshultz SE,Liu W,Loane M,Ohno SL,Lyons R,Mabweijano J,MacIntyre MF,Malekzadeh R,Mallinger L,Manivannan S,Marcenes W,March L,Margolis DJ,Marks GB,Marks R,Matsumori A,Matzopoulos R,Mayosi BM,McAnulty JH,McDermott MM,McGill N,McGrath J,Medina-Mora ME,Meltzer M,Mensah GA,Merriman TR,Meyer AC,Miglioli V,Miller M,Miller TR,Mitchell PB,Mock C,Mocumbi AO,Moffitt TE,Mokdad AA,Monasta L,Montico M,Moradi-Lakeh M,Moran A,Morawska L,Mori R,Murdoch ME,Mwaniki MK,Naidoo K,Nair MN,Naldi L,Narayan KM,Nelson PK,Nelson RG,Nevitt MC,Newton CR,Nolte S,Norman P,Norman R,O’Donnell M,O’Hanlon S,Olives C,Omer SB,Ortblad K,Osborne R,Ozgediz D,Page A,Pahari B,Pandian JD,Rivero AP,Patten SB,Pearce N,Padilla RP,Perez-Ruiz F,Perico N,Pesudovs K,Phillips D,Phillips MR,Pierce K,Pion S,Polanczyk GV,Polinder S,Pope CA 3rd,Popova S,Porrini E,Pourmalek F,Prince M,Pullan RL,Ramaiah KD,Ranganathan D,Razavi H,Regan M,Rehm JT,Rein DB,Remuzzi G,Richardson K,Rivara FP,Roberts T,Robinson C,De Leòn FR,Ronfani L,Room R,Rosenfeld LC,Rushton L,Sacco RL,Saha S,Sampson U,Sanchez-Riera L,Sanman E,Schwebel DC,Scott JG,Segui-Gomez M,Shahraz S,Shepard DS,Shin H,Shivakoti R,Singh D,Singh GM,Singh JA,Singleton J,Sleet DA,Sliwa K,Smith E,Smith JL,Stapelberg NJ,Steer A,Steiner T,Stolk WA,Stovner LJ,Sudfeld C,Syed S,Tamburlini G,Tavakkoli M,Taylor HR,Taylor JA,Taylor WJ,Thomas B,Thomson WM,Thurston GD,Tleyjeh IM,Tonelli M,Towbin JA,Truelsen T,Tsilimbaris MK,Ubeda C,Undurraga EA,van der Werf MJ,van Os J,Vavilala MS,Venketasubramanian N,Wang M,Wang W,Watt K,Weatherall DJ,Weinstock MA,Weintraub R,Weisskopf MG,Weissman MM,White RA,Whiteford H,Wiebe N,Wiersma ST,Wilkinson JD,Williams HC,Williams SR,Witt E,Wolfe F,Woolf AD,Wulf S,Yeh PH,Zaidi AK,Zheng ZJ,Zonies D,Lopez AD,AlMazroa MA,Memish ZA.Disability-adjusted life years(DALYs)for 291 diseases and injuries in 21 regions,1990-2010:a systematic analysis for the Global Burden of Disease Study 2010.Lancet 2012;380:2197-2223[PMID:23245608 DOI:10.1016/S0140-6736(12)61689-4]
26 Wang FS,Fan JG,Zhang Z,Gao B,Wang HY.The global burden of liver disease:the major impact of China.Hepatology 2014;60:2099-2108[PMID:25164003 DOI:10.1002/hep.27406]
27 Gon?alves PL,Zago-Gomes Mda P,Marques CC,Mendon?a AT,Gon?alves CS,Pereira FE.Etiology of liver cirrhosis in Brazil:chronic alcoholism and hepatitis viruses in liver cirrhosis diagno-sed in the state of Espírito Santo.Clinics(Sao Paulo)2013;68:291-295[PMID:23644846 DOI:10.6061/clinics/2013(03)OA02]
28 Mukherjee PS,Vishnubhatla S,Amarapurkar DN,Das K,Sood A,Chawla YK,Eapen CE,Boddu P,Thomas V,Varshney S,Hidangmayum DS,Bhaumik P,Thakur B,Acharya SK,Chowdhury A.Etiology and mode of presentation of chronic liver diseases in India:A multi centric study.PLo S One 2017;12:e0187033[PMID:29073197 DOI:10.1371/journal.pone.0187033]
29 Méndez-Sánchez N,Villa AR,Chávez-Tapia NC,Ponciano-Rodriguez G,Almeda-Valdés P,González D,Uribe M.Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data.Ann Hepatol 2005;4:52-55[PMID:15798662]
30 Torres-Valadez R,Roman S,Jose-Abrego A,Sepulveda-Villegas M,Ojeda-Granados C,Rivera-I?iguez I,Panduro A.Early Detection of Liver Damage in Mexican Patients with Chronic Liver Disease.J Transl Int Med 2017;5:49-57[PMID:28680839DOI:10.1515/jtim-2017-0003]
31 Arrese M,Feldstein AE.Nash-Related Cirrhosis:An Occult Liver Disease Burden.Hepatol Commun 2017;1:84-86[PMID:29335681 DOI:10.1002/hep4.1033]
32 Younossi ZM,Koenig AB,Abdelatif D,Fazel Y,Henry L,Wymer M.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes.Hepatology 2016;64:73-84[PMID:26707365 DOI:10.1002/hep.28431]
33 Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLDin Asia.J Hepatol 2017;67:862-873[PMID:28642059 DOI:10.1016/j.jhep.2017.06.003]
34 Wong VW.Nonalcoholic fatty liver disease in Asia:a story of growth.J Gastroenterol Hepatol 2013;28:18-23[PMID:23094755DOI:10.1111/jgh.12011]
35 Kojima S,Watanabe N,Numata M,Ogawa T,Matsuzaki S.Increase in the prevalence of fatty liver in Japan over the past 12years:analysis of clinical background.J Gastroenterol 2003;38:954-961[PMID:14614602 DOI:10.1007/s00535-003-1178-8]
36 Hu X,Huang Y,Bao Z,Wang Y,Shi D,Liu F,Gao Z,Yu X.Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units.BMC Gastroenterol 2012;12:123[PMID:22978800 DOI:10.1186/1471-230X-12-123]
37 Wei JL,Leung JC,Loong TC,Wong GL,Yeung DK,Chan RS,Chan HL,Chim AM,Woo J,Chu WC,Wong VW.Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients:A Population Study Using Proton-Magnetic Resonance Spectroscopy.Am J Gastroenterol 2015;110:1306-14;quiz 1315[PMID:26215532 DOI:10.1038/ajg.2015.235]
38 Li H,Wang YJ,Tan K,Zeng L,Liu L,Liu FJ,Zhou TY,Chen EQ,Tang H.Prevalence and risk factors of fatty liver disease in Chengdu,Southwest China.Hepatobiliary Pancreat Dis Int 2009;8:377-382[PMID:19666406]
39 Nader LA,de Mattos AA,Bastos GA.Burden of liver disease in Brazil.Liver Int 2014;34:844-849[PMID:24422599 DOI:10.1111/liv.12470]
40 de Carvalho JR,Villela-Nogueira CA,Perez RM,Portugal FB,Flor LS,Campos MR,Schramm JMA.Burden of Chronic Viral Hepatitis and Liver Cirrhosis in Brazil-the Brazilian Global Burden of Disease Study.Ann Hepatol 2017;16:893-900[PMID:29055917 DOI:10.5604/01.3001.0010.5280]
41 Pereira LM,Martelli CM,Moreira RC,Merchan-Hamman E,Stein AT,Cardoso MR,Figueiredo GM,Montarroyos UR,Braga C,Turchi MD,Coral G,Crespo D,Lima ML,Alencar LC,Costa M,dos Santos AA,Ximenes RA.Prevalence and risk factors of Hepatitis C virus infection in Brazil,2005 through 2009:a cross-sectional study.BMC Infect Dis 2013;13:60[PMID:23374914DOI:10.1186/1471-2334-13-60]
42 Singal AK,Anand BS.Recent trends in the epidemiology of alcoholic liver disease.Clin Liver Dis 2013;2:53-56[DOI:10.1002/cld.168]
43 Ratib S,West J,Fleming KM.Liver cirrhosis in England-an observational study:are we measuring its burden occurrence correctly?BMJ Open 2017;7:e013752[PMID:28710203 DOI:10.1136/bmjopen-2016-013752]
44 Fleming KM,Aithal GP,Solaymani-Dodaran M,Card TR,West J.Incidence and prevalence of cirrhosis in the United Kingdom,1992-2001:a general population-based study.J Hepatol 2008;49:732-738[PMID:18667256 DOI:10.1016/j.jhep.2008.05.023]
45 Armstrong MJ,Houlihan DD,Bentham L,Shaw JC,Cramb R,Olliff S,Gill PS,Neuberger JM,Lilford RJ,Newsome PN.Pre-sence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.J Hepatol 2012;56:234-240[PMID:21703178 DOI:10.1016/j.jhep.2011.03.020]
46 Davis GL,Albright JE,Cook SF,Rosenberg DM.Projecting future complications of chronic hepatitis C in the United States.Liver Transpl 2003;9:331-338[PMID:12682882 DOI:10.1053/jlts.2003.50073]